Health China
EpiCongress Boston
DoubleTree Suites by Hilton Hotel Boston
400 Soldiers Field Road
Boston, USA
EpiCongress Boston
Hanson Wade
DoubleTree Suites by Hilton Hotel Boston
400 Soldiers Field Road

Schedule of Presentations:

Tuesday, July 23, 2013
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
09:00:00 Epigenomics Data Management and Visualization Strategies
13:00:00 Bridging Epigenetic Mechanisms and Stem Cell Biology Zong Ling Wang
Wednesday, July 24, 2013
06:00:00 New Presentation
06:00:00 New Presentation
08:15:00 Chairman’s Opening Remarks
08:30:00 An update on Epizyme’s first clinical candidate molecule Robert Gould
09:00:00 Developing Specific Assays to Bridge the Knowledge Gap in Epigenetic Pathways
09:30:00 Epigenetic Drug Discovery: Are we Inspired by History or Deluded by it?
10:00:00 Morning Refreshments & Speed Networking
11:30:00 Exploring Histone Methyltransferase EZH2 as an Epigenetic Target For Cancer Therapy Caretha Creasy
11:30:00 Genetic Drivers of Altered Epigenomic States in B Cell Lymphoma: Opportunities for Therapeutic Manipulation Russell J. H. Ryan
11:30:00 Clinical Case Study: Using PK/PD Endpoints for Dose-Ranging in Early Clinical Development of Epigenetic Drugs
12:00:00 Methylomic Alterations in Pathogenesis and Classification of Cancer Amit Verma
12:00:00 A Candidate Gene Approach to Exploring the Role of DNA Methylation in Breast Cancer Disparities Garth Rauscher
12:00:00 Therapeutic Opportunities for EZH2 Histone Methyltransferases in Blood Malignancies and Lymphoma
12:30:00 Translating Chromatin Modulation To Drug Discovery: Inhibition Of EZH2
12:30:00 Defining the Functional Consequences of Isoform Specific Inhibition of the Class I HDACs Using a Chemical Genetics Approach Edward Holson
12:30:00 Discovery and Development of a Mechanism-Based Epigenetic Biomarker for Lung Cancer Trials David Shames
13:00:00 Lunch & Networking
13:00:00 Lunch & Networking
13:00:00 Panel Discussion: Discovering Clinic Biomarkers and Improving Patient Selection
13:30:00 Lunch & Networking
14:00:00 Translational Development of Second Generation Class Selective HDACi’s: Analogs of the Natural Product Largazole John Pilon
14:00:00 The Therapeutic Potential of Jumonji Histone Demethylase Inhibitors Peter Staller
14:30:00 Panel Discussion: Developing Specific Epigenetic Assays Peter Staller
14:30:00 Discovery and Development of Specific LSD1 Inhibitor Sunil Sharma
14:30:00 Targeting on Epigenetic Reader for Cancer Therapy Jun Qi
15:00:00 RVX-208; the First BET-Protein Inhibitor Tested in Human Clinical Trials
15:30:00 Afternoon Refreshments & Networking
16:00:00 Using Computational Analysis to Map out the Drugability Landscape of Epigenetic Targets
16:30:00 Using Chemical Probes to Aid Epigenetic Target Validation - unpublished data Mark Bunnage
17:00:00 Panel Discussion: Improving Target Validation and Prioritization Peter J Tummino, Holger Patzke
17:30:00 Chairman’s Closing Remarks
17:45:00 Poster Session - Present your latest work to the audience during our open poster session
Thursday, July 25, 2013
06:00:00 New Presentation
08:45:00 Chairman’s Opening Remarks Mark Bunnage
09:00:00 Selective Inhibitors of HDAC1/2 and Induction of Fetal Globin: Novel Treatment for Sickle Cell Disease and β-Thallasemia Simon Jones
09:30:00 Chemogenomic Approaches To Spatiotemporal Regulation Of HDAC Activity
10:00:00 Morning Refreshments & Networking
10:30:00 Prospects for BET Inhibitors in Solid Tumors Peter J Tummino
10:30:00 Targeting the Substrate Binding Site of Methyltranferases: Structure Based Design of SMYD2 Inhibitors Scott Cowen
10:30:00 Genome Regulation in Health and Disease Richard Young
11:00:00 Epigenetic Regulation Of Resistance To Anti-Cancer Drugs Jeffrey Settleman
11:00:00 Chromatin Maps and Epigenomic Features of Normal and Malignant Hematopoietic Development Mazhar Adli
11:00:00 Discovering Chemical Probes of Histone Methyltransferases Jian Jin
11:30:00 Recruitment of Chromatin Modifying Activities by DNA binding proteins Jinrong Min
11:30:00 Targeting the SAM Binding Sites of Methyltranferases to Identify Novel Inhibitors Kenneth J. Eilertsen
11:30:00 Selecting Patients for Entinostat in a Phase 2 Trial Peter Ordentlich
12:00:00 Lunch & Networking
12:00:00 Lunch & Networking
12:00:00 Lunch & Networking
13:00:00 The Promise of Epigenetic Therapy in Solid Tumors – Lessons Being Learned from Current Drugs Stephen B Baylin
13:00:00 Selectively Activating Gene Expression by Targeting Non-Coding RNA
13:30:00 Coming to Grips with Heterogeneity in Neuropsychiatric Disorders: Epigenetic Analytic and Therapeutic Approaches Curtis Deutsch
13:30:00 Thinking Outside the Box when Developing Chromatin Interacting Drugs Steven Landau
13:30:00 CC-486 Priming in Solid Tumors to Improve Chemotherapy Efficacy
14:00:00 Cancer, Schizophrenia and Autism: Comparing Environmental and Epigenomic Components
14:00:00 Afternoon Refreshments & Networking
14:30:00 How is the SGC Helping To Push Innovation in the Field? Cheryl Arrowsmith
15:00:00 Investing in Epigenetics: A Venture Capitalist Perspective on Raising Long Term Funding
15:30:00 Realizing the Potential for the First-in-Class Selective LSD1 Inhibitor Jonathan Northrup
16:00:00 Chairman’s Closing Remarks & Close of Conference Mark Bunnage
Friday, July 26, 2013
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
06:00:00 New Presentation
09:00:00 Translating Epigenetic Regulation to Clinical Oncology Hella Kohlhof
13:00:00 Pathway-based Application of Epigenetic Drugs to Optimize Clinical Safety and Efficacy
Biotech China 2014
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.